Paul Martin

Overview:

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Positions:

Professor of Pediatrics

Pediatrics, Transplant and Cellular Therapy
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1987

Washington University in St. Louis

Ph.D. 1987

Washington University in St. Louis

Intern, Pediatrics

Yale University

Resident, Pediatrics

Yale University

Fellow, Pediatric Hematology/Oncology, Pediatrics

Yale University

Grants:

Pediatric Oncology Group (POG)

Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia

Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Novartis Pharmaceuticals Corporation
Role
Principal Investigator
Start Date
End Date

A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Jazz Pharmaceuticals
Role
Principal Investigator
Start Date
End Date

PBMTC SUP 1601 Pathogen Identification in Pediatric HSCT

Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
Children's Hospital Los Angeles
Role
Principal Investigator
Start Date
End Date

A Phase 2 Multicenter Single arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory pALL

Administered By
Pediatrics, Transplant and Cellular Therapy
Awarded By
MedImmune, Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.

BACKGROUND: Minimal residual disease (MRD) after induction therapy is one of the strongest prognostic factors in childhood acute lymphoblastic leukemia (ALL), and MRD-directed treatment intensification improves survival. Little is known about the effects of inherited genetic variants on interpatient variability in MRD. METHODS: A genome-wide association study was performed on 2597 children on the Children's Oncology Group AALL0232 trial for high-risk B-cell ALL. Association between genotype and end-of-induction MRD levels was evaluated for 863 370 single nucleotide polymorphisms (SNPs), adjusting for genetic ancestry and treatment strata. Top variants were further evaluated in a validation cohort of 491 patients from the Children's Oncology Group P9905 and 6 ALL trials. The independent prognostic value of single nucleotide polymorphisms was determined in multivariable analyses. All statistical tests were 2-sided. RESULTS: In the discovery genome-wide association study, we identified a genome-wide significant association at the GATA3 locus (rs3824662, odds ratio [OR] = 1.58, 95% confidence interval [CI] = 1.35 to 1.84; P = 1.15 × 10-8 as a dichotomous variable). This association was replicated in the validation cohort (P = .003, MRD as a dichotomous variable). The rs3824662 risk allele independently predicted ALL relapse after adjusting for age, white blood cell count, and leukemia DNA index (P = .04 and .007 in the discovery and validation cohort, respectively) and remained prognostic when the analyses were restricted to MRD-negative patients (P = .04 and .03 for the discovery and validation cohorts, respectively). CONCLUSION: Inherited GATA3 variant rs3824662 strongly influences ALL response to remission induction therapy and is associated with relapse. This work highlights the potential utility of germline variants in upfront risk stratification in ALL.
Authors
Zhang, H; Liu, AP-Y; Devidas, M; Lee, SH; Cao, X; Pei, D; Borowitz, M; Wood, B; Gastier-Foster, JM; Dai, Y; Raetz, E; Larsen, E; Winick, N; Bowman, WP; Karol, S; Yang, W; Martin, PL; Carroll, WL; Pui, C-H; Mullighan, CG; Evans, WE; Cheng, C; Hunger, SP; Relling, MV; Loh, ML; Yang, JJ
MLA Citation
Zhang, Hui, et al. “Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.J Natl Cancer Inst, vol. 113, no. 4, Apr. 2021, pp. 408–17. Pubmed, doi:10.1093/jnci/djaa138.
URI
https://scholars.duke.edu/individual/pub1459998
PMID
32894760
Source
pubmed
Published In
J Natl Cancer Inst
Volume
113
Published Date
Start Page
408
End Page
417
DOI
10.1093/jnci/djaa138

Effects of Vitamin D Levels on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children

Authors
Bajwa, RPS; Taylor, K; Hoyt, AR; Kamboj, M; Auletta, JJ; Stanek, J; Mahadeo, KM; Alsaedi, HS; Abdel-Azim, H; Dvorak, CC; O'Kane, S; Stafford, L; Martin, PL
MLA Citation
Bajwa, Rajinder P. S., et al. “Effects of Vitamin D Levels on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children.” Biology of Blood and Marrow Transplantation, vol. 25, no. 3, 2019.
URI
https://scholars.duke.edu/individual/pub1469333
Source
wos-lite
Published In
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Volume
25
Published Date

Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis

Authors
Buechner, J; Grupp, SA; Maude, SL; Boyer, M; Bittencourt, H; Laetsch, TW; Bader, P; Verneris, MR; Stefanski, H; Myers, GD; Qayed, M; Pulsipher, MA; De Moerloose, B; Hiramatsu, H; Schlis, K; Davis, K; Martin, PL; Nemecek, E; Peters, C; Wood, P; Taran, T; Mueller, KT; Zhang, Y; Rives, S
MLA Citation
Buechner, Jochen, et al. “Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis.” Clinical Lymphoma Myeloma and Leukemia, vol. 17, Elsevier BV, 2017, pp. S263–64. Crossref, doi:10.1016/j.clml.2017.07.030.
URI
https://scholars.duke.edu/individual/pub1457166
Source
crossref
Published In
Clinical Lymphoma, Myeloma & Leukemia
Volume
17
Published Date
Start Page
S263
End Page
S264
DOI
10.1016/j.clml.2017.07.030

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.

Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.
Authors
Ragoonanan, D; Khazal, SJ; Abdel-Azim, H; McCall, D; Cuglievan, B; Tambaro, FP; Ahmad, AH; Rowan, CM; Gutierrez, C; Schadler, K; Li, S; Di Nardo, M; Chi, L; Gulbis, AM; Shoberu, B; Mireles, ME; McArthur, J; Kapoor, N; Miller, J; Fitzgerald, JC; Tewari, P; Petropoulos, D; Gill, JB; Duncan, CN; Lehmann, LE; Hingorani, S; Angelo, JR; Swinford, RD; Steiner, ME; Hernandez Tejada, FN; Martin, PL; Auletta, J; Choi, SW; Bajwa, R; Dailey Garnes, N; Kebriaei, P; Rezvani, K; Wierda, WG; Neelapu, SS; Shpall, EJ; Corbacioglu, S; Mahadeo, KM
MLA Citation
Ragoonanan, Dristhi, et al. “Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.Nat Rev Clin Oncol, Feb. 2021. Pubmed, doi:10.1038/s41571-021-00474-4.
URI
https://scholars.duke.edu/individual/pub1474851
PMID
33608690
Source
pubmed
Published In
Nature Reviews. Clinical Oncology
Published Date
DOI
10.1038/s41571-021-00474-4

Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial

Authors
Grupp, SA; Maude, SL; Rives, S; Baruchel, A; Boyer, M; Bittencourt, H; Bader, P; Buchner, J; Laetsch, TW; Stefanski, H; Myers, GD; Qayed, M; Pulsipher, MA; De Moerloose, B; Yanik, GA; Davis, KL; Martin, PL; Nemecek, ER; Peters, C; Krueger, J; Sr, BA; Boissel, N; Mechinaud, F; Leung, M; Eldjerou, L; Bleickardt, E; Mueller, KT; Hiramatsu, H
URI
https://scholars.duke.edu/individual/pub1469334
Source
wos-lite
Published In
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Volume
25
Published Date